Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
On August 19, 2021, Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition into the role of Executive Chairman while Joaquin Duato, currently Vice Chairman, will become CEO, effective January 3, 2022. Gorsky has led the company as CEO since 2012, overseeing a 60% increase in R&D investments, reaching $12 billion in 2020. He emphasized the company's strong performance across all segments. Duato expressed enthusiasm for leading the company, highlighting its unmatched healthcare platform. The Board acknowledged the effective succession planning that enabled this leadership transition.
On August 12, 2021, Johnson & Johnson (NYSE: JNJ) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 15, 2021. The company will be represented by Joseph J. Wolk, Executive Vice President and CFO, and Mathai Mammen, Global Head of Research & Development, during a session at 9:30 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website, with a replay available 48 hours post-event.
Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on September 10, 2021. The event will feature Thibaut Mongon, Executive Vice President Worldwide Chairman of Consumer Health, speaking at 9:20 a.m. (Eastern Time). Investors and other interested parties can access the webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.
On July 29, 2021, lawmakers proposed reforms to prevent companies like Johnson & Johnson (JNJ) from using bankruptcy to evade liabilities related to talc products linked to ovarian cancer. The Nondebtor Release Prohibition Act aims to close loopholes such as non-consensual third-party releases and the Texas Two-Step strategy. JNJ has a market cap exceeding $400 billion and reported a 27% year-over-year sales increase to $23.31 billion, upgrading its annual forecast to $94.6 billion. Advocacy groups highlight the ethical implications of JNJ's potential bankruptcy strategy, stressing the need for corporate accountability.
Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on September 10, 2021. Joaquin Duato, Vice Chairman of the Executive Committee, is set to represent the company in a session starting at 10:00 a.m. Eastern Time. Interested investors can access the live webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) reported impressive Q2 results with sales of $23.3 billion, up 27.1% year-over-year. Net earnings surged 73.1% to $6.3 billion, resulting in a diluted EPS of $2.35, a 72.8% increase. Key growth drivers included a 62.7% rise in Medical Devices sales, bolstered by market recovery from COVID-19, and a 17.2% increase in Pharmaceuticals, highlighted by strong performances from STELARA and DARZALEX. The Consumer Health segment also contributed with a 13.3% growth, driven by skin health products. JNJ emphasized ongoing innovations and external regulatory approvals.
Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the third quarter of 2021. This dividend is set to be paid on September 7, 2021, to shareholders on record by August 24, 2021. The ex-dividend date is August 23, 2021. Johnson & Johnson continues its commitment to shareholder returns while focusing on improving health access and affordability globally.
Attorneys representing women diagnosed with ovarian cancer linked to Johnson & Johnson's (NYSE: JNJ) talc products are condemning potential bankruptcy plans aimed at limiting the company's liability. Reports suggest J&J, with a market cap of $443 billion, may exploit bankruptcy to mitigate financial responsibilities from ongoing lawsuits. Lawyers highlight a history of dangerous practices, including the company's failure to replace talc with safer alternatives. A previous $2.1 billion judgment against J&J reflects significant negligence. Critics argue bankruptcy filings would deny victims justice.
On July 15, 2021, Beasley Allen law firm filed a federal class-action lawsuit against Johnson & Johnson (NYSE: JNJ) for selling benzene-tainted sunscreen products from its subsidiaries Neutrogena and Aveeno. The lawsuit seeks damages for consumers who purchased the affected items, which were recalled after lab tests revealed benzene levels exceeding safe limits. Benzene is a hazardous chemical linked to leukemia, raising serious health concerns, especially for children. The FDA prohibits benzene in sun-care products, yet J&J's recall only includes spray products.
Johnson & Johnson Consumer Inc. (NYSE: JNJ) is recalling all lots of five aerosol sunscreen products due to low levels of benzene detected in some samples. This voluntary recall includes NEUTROGENA Beach Defense, Cool Dry Sport, Invisible Daily, Ultra Sheer, and AVEENO Protect + Refresh. Benzene, a human carcinogen, is not an ingredient but was found in finished products. While daily exposure at detected levels is not expected to cause harm, the recall emphasizes consumer safety. Consumers are instructed to stop using these products and contact the Consumer Care Center for refunds.